Added to YB: 2025-10-01
Pitch date: 2025-09-29
PMVP [neutral]
PMV Pharmaceuticals, Inc.
-11.11%
current return
Author Info
No bio for this author
Company Info
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
Market Cap
$75.7M
Pitch Price
$1.44
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.21
P/E
-0.96
EV/Sales
N/A
Sector
Biotechnology
Category
value
Special Situations Round-Up 39/25 - PMV Pharmaceuticals, Inc.
PMVP (quick overview): Oncology biotech w/ $148M cash, runway to Q1'27, trades 0.58x NCAV at $78M mcap. Promising Phase 2 interim data for solid tumor candidate but market unimpressed. Prolific biotech activist Kevin Tang owns 8.9% stake, acquired 6 failed biotechs in 2024, potential buyout catalyst.
Read full article (1 min)